APRE Aprea Therapeutics, Inc.
Healthcare$0.91-4.21%ClosedMarket Cap: $5.9M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.17
P/S
52.24
EV/EBITDA
3.21
DCF Value
$2.13
FCF Yield
-198.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1523.6%
Operating Margin
-10649.9%
Net Margin
-10121.7%
ROE
-59.5%
ROA
-24.8%
ROIC
-29.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-3.4M | $-3.3M | $— | — |
| Q4 null | $0.00 | NaN% | $-2.6M | $-2.5M | $— | — |
| FY null | $0.00 | NaN% | $-13.2M | $-12.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-3.1M | $-3.0M | $— | — |
| Q2 null | $118.1K | -1519.0% | $-3.4M | $-3.2M | $— | — |
| Q1 null | $162.5K | -1428.4% | $-4.1M | $-3.9M | $— | — |
| Q4 null | $205.8K | -1046.2% | $-3.2M | $-2.9M | $— | — |
| FY null | $1.5M | -523.2% | $-14.3M | $-13.0M | $— | — |
| Q3 null | $354.6K | -702.7% | $-4.1M | $-3.8M | $— | — |
| Q2 null | $561.6K | -355.4% | $-3.8M | $-3.5M | $— | — |
| Q1 null | $380.6K | -320.5% | $-3.1M | $-2.8M | $— | — |
| Q4 2023 | $14.1K | -14434.2% | $-3.7M | $-3.4M | $-0.92 | — |